ArticleJournal of translational medicine2025
Spatial profiling reveals unique immune microenvironment in premenopausal triple-negative breast cancer associated with therapy response.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Integrated molecular and immune profiling identifies FOXA1 as a complementary co-target to MUC1 for bispecific immunotherapy in breast cancer.Functional & integrative genomics · 2026Article
- Spatial organization of the TNBC tumor microenvironment: multicellular niches, T-cell bottlenecks, and therapeutic opportunities.Journal of translational medicine · 2026Review
- Age and sex: dual drivers remodeling the anti-tumor immune microenvironment and shaping personalized immuno-oncology.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundTriple-negative breast cancer (TNBC) lacks targeted therapies, leading to a poor prognosis. Younger patients with TNBC often present with aggressive disease and exhibit distinct tumor microenvironments (TME). We performed spatial profiling to understand the influence of menopausal status on the immune environment, tumor progression, and therapy response.
methodsEleven treatment-naive TNBC tumors were examined in epithelial and non-epithelial areas using digital spatial profiling to identify differentially expressed markers and pathways. Deconvolution methods were employed to identify immune cell subtypes, and the protein expression of T and B cells was confirmed. The prognostic utility of the identified genes and pathways was validated using the METABRIC and SCAN-B datasets. The expression of target genes was analyzed in the I-SPY 2 trial data to understand their influence on the response to specific therapies.
resultsPremenopausal tumors formed a distinct cluster characterized by the upregulation of cell activation and antigen presentation pathways. In contrast, T cell checkpoint, cancer antigen, and PI3K-AKT pathways were downregulated. External datasets validated these findings, showing a lower hazard and better prognosis for genes upregulated in premenopausal tumors. An enrichment of CD8 + T cells, endothelial cells, and monocytes was observed, along with increased intratumoral protein expression of CD8, CD4, and CD20. Premenopausal tumors demonstrated better responses to PARP and HSP90 inhibitors but showed lower sensitivity to Pembrolizumab and PI3K-AKT inhibitors compared to postmenopausal tumors in the I-SPY 2 trial data.
conclusionOur study underscores the importance of menopausal status in shaping the TME within TNBC, revealing distinct immune landscapes and therapy responses. These findings highlight the need for larger prospective studies to validate differential treatment strategies in younger patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.